Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

U.S. Food and Drug Administration approved Alnylam's drug to treat a rare and deadly heart disease on Thursday, allowing the ...

JPMorgan upgraded Alnylam (ALNY) to Overweight from Neutral with a price target of $328, up from $280. The firm increased TTR silencer ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major ...